Immune Checkpoint Blockade in Cancer Therapy
- PMID: 25605845
- PMCID: PMC4980573
- DOI: 10.1200/JCO.2014.59.4358
Immune Checkpoint Blockade in Cancer Therapy
Abstract
Immunologic checkpoint blockade with antibodies that target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathway (PD-1/PD-L1) have demonstrated promise in a variety of malignancies. Ipilimumab (CTLA-4) and pembrolizumab (PD-1) are approved by the US Food and Drug Administration for the treatment of advanced melanoma, and additional regulatory approvals are expected across the oncologic spectrum for a variety of other agents that target these pathways. Treatment with both CTLA-4 and PD-1/PD-L1 blockade is associated with a unique pattern of adverse events called immune-related adverse events, and occasionally, unusual kinetics of tumor response are seen. Combination approaches involving CTLA-4 and PD-1/PD-L1 blockade are being investigated to determine whether they enhance the efficacy of either approach alone. Principles learned during the development of CTLA-4 and PD-1/PD-L1 approaches will likely be used as new immunologic checkpoint blocking antibodies begin clinical investigation.
© 2015 by American Society of Clinical Oncology.
Conflict of interest statement
Authors' disclosures of potential conflicts of interest are found in the article online at
Figures
Similar articles
-
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Clin Ther. 2015. PMID: 25823918 Free PMC article. Review.
-
Immune checkpoint inhibitors for nonsmall cell lung cancer treatment.J Chin Med Assoc. 2017 Jan;80(1):7-14. doi: 10.1016/j.jcma.2016.08.005. Epub 2016 Sep 29. J Chin Med Assoc. 2017. PMID: 27693088 Review.
-
Managing immune checkpoint-blocking antibody side effects.Am Soc Clin Oncol Educ Book. 2015:76-83. doi: 10.14694/EdBook_AM.2015.35.76. Am Soc Clin Oncol Educ Book. 2015. PMID: 25993145 Review.
-
Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.Eur J Cancer. 2017 Sep;82:56-65. doi: 10.1016/j.ejca.2017.05.038. Epub 2017 Jun 22. Eur J Cancer. 2017. PMID: 28648699
-
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?Curr Opin Immunol. 2015 Apr;33:23-35. doi: 10.1016/j.coi.2015.01.006. Epub 2015 Jan 23. Curr Opin Immunol. 2015. PMID: 25621841 Review.
Cited by
-
The Good (Tumor Killing) and the Bad (Cardiovascular Complications) of Immunologic Checkpoint Inhibitors.Curr Cardiol Rep. 2024 Oct 23. doi: 10.1007/s11886-024-02147-x. Online ahead of print. Curr Cardiol Rep. 2024. PMID: 39441327 Review.
-
Risk factors for relapse of immune-related pneumonitis after 6-week oral prednisolone therapy: a follow-up analysis of a phase II study.BMC Pulm Med. 2024 Oct 8;24(1):495. doi: 10.1186/s12890-024-03284-3. BMC Pulm Med. 2024. PMID: 39379903 Free PMC article. Clinical Trial.
-
Sarcopenia predicts immune-related adverse events due to anti-PD-1/PD-L1 therapy in patients with advanced lung cancer.Front Oncol. 2024 Sep 23;14:1450020. doi: 10.3389/fonc.2024.1450020. eCollection 2024. Front Oncol. 2024. PMID: 39376979 Free PMC article.
-
Low pre-immunotherapy forced vital capacity is associated with poor outcomes in non-small cell lung cancer patients receiving immunotherapy regardless of prior treatment history.Ther Adv Med Oncol. 2024 Sep 25;16:17588359241281480. doi: 10.1177/17588359241281480. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39371616 Free PMC article.
-
Long-term treatment results of pembrolizumab monotherapy: reconsideration of immune checkpoint inhibitor monotherapy.J Rural Med. 2024 Oct;19(4):273-278. doi: 10.2185/jrm.2024-014. Epub 2024 Oct 1. J Rural Med. 2024. PMID: 39355159 Free PMC article.
References
-
- Schneider H, Downey J, Smith A, et al. Reversal of the TCR stop signal by CTLA-4. Science. 2006;313:1972–1975. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials